Arrowhead Pharmaceuticals, Inc.(ARWR)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
ARWR | 12.22 B | -38.96x | 1.71% | -47.79% | $-2.22 | -55.21% | 2.96 | - | $95.49 | $22.73 |
SMMT | 13.67 B | -15.43x | - | - | $-1.11 | -1.93% | 3.24 | - | $29.23 | $12.07 |
BMRN | 12.86 B | 179.54x | 19.90% | 2.14% | $0.37 | 1.18% | 0.66 | - | $70.98 | $49.26 |
MDGL | 12.54 B | -38.79x | 71.20% | -25.32% | $-13.99 | -53.31% | 0.66 | - | $615.00 | $393.61 |
IONS | 9.66 B | -16.70x | -40.70% | -64.66% | $-3.48 | -1.05% | 4.98 | - | $86.74 | $49.13 |
Peer Valuation & Performance Analysis
Peer group analysis for Arrowhead Pharmaceuticals, Inc. (ARWR) compared to its primary competitors (including SMMT, BMRN, MDGL) reveals distinct metrics. ARWR trades at a valuation discount relative to its competitors, with a P/E ratio of -39.0x versus the peer average of 27.2x (representing a 243% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, ARWR's revenue growth of 1.7% lags behind the peer average of 16.8%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of -47.8% is below the peer average of -29.3%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• ARWR ranks #0 in P/E ratio, #3 in revenue growth, and #4 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $85.18 | $86.79 | $83.46 | $86.49 | 1,370,500 | +1.54% |
| 2026-09-02 | $82.87 | $85.47 | $82.08 | $85.37 | 1,525,400 | +3.02% |
| 2026-09-01 | $81.14 | $83.27 | $80.76 | $82.74 | 1,330,600 | +1.97% |
| 2026-08-31 | $83.13 | $83.75 | $80.75 | $82.39 | 1,595,500 | -0.89% |
| 2026-08-28 | $87.99 | $88.25 | $84.19 | $84.91 | 1,282,200 | -3.50% |
| 2026-08-27 | $89.59 | $89.59 | $88.06 | $88.59 | 857,500 | -1.12% |
| 2026-08-26 | $88.45 | $89.83 | $86.80 | $89.12 | 859,500 | +0.76% |
| 2026-08-25 | $88.00 | $90.21 | $87.00 | $88.88 | 983,000 | +1.00% |
| 2026-08-24 | $86.77 | $87.01 | $85.50 | $86.73 | 1,104,400 | -0.05% |
| 2026-08-21 | $87.90 | $88.46 | $85.94 | $87.11 | 1,089,800 | -0.90% |
| 2026-08-20 | $88.23 | $88.45 | $85.90 | $87.47 | 896,800 | -0.86% |
| 2026-08-19 | $89.51 | $90.00 | $87.58 | $89.41 | 1,363,400 | -0.11% |
| 2026-08-18 | $87.72 | $88.35 | $85.98 | $87.90 | 971,200 | +0.21% |
| 2026-08-17 | $86.44 | $88.94 | $86.26 | $88.70 | 929,700 | +2.61% |
| 2026-08-14 | $84.75 | $87.17 | $83.78 | $86.64 | 818,000 | +2.23% |
Explore More Analysis for ARWR
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.